What happened
MedCity News reports that Iambic Therapeutics priced more than 9.37 million IPO shares at $16 each and began trading on Nasdaq under IAM. The San Diego biotech plans to use the proceeds to fund clinical development of cancer drugs and continued investment in its AI-centered drug-discovery platform.
MedCity News reports that Iambic priced more than 9.37 million shares at $16 each, raising $150 million, with the shares beginning Nasdaq trading under the symbol IAM. The report says the company had $207.8 million in cash at the end of the second quarter and expects the combined funds to support operations into the fourth quarter of 2028.
According to MedCity News, Iambic combines AI models with automated high-throughput experiments spanning hit identification through clinical developability. The company calls this approach “molecular superintelligence” and says its continuous experimentation improves predictions and search strategies. Its lead program, IAM1363, is an oral HER2 inhibitor designed to address multiple protein variants and penetrate the brain. IAM1364 is in Phase 1/1b testing for advanced or metastatic solid tumors with HER2 alterations; IAM217 and IAM-C1 are expected to enter clinical testing.
The report says Iambic plans to spend $75 million on IAM1363’s Phase 1 program and potential Phase 2 studies, about $15 million each on IAM217 and IAM-C1 testing, and $20 million on continued platform investment. MedCity News also reports collaboration revenue of $12.7 million in the first half of the year, compared with $3.9 million in the same period last year.
Source details: medcitynews.com ↗
Why it matters
The financing gives Iambic substantial capital to test whether its combination of AI models and automated high-throughput experiments can produce clinically useful cancer medicines. The company’s lead program is already in early-stage human testing, but the source provides no independent evidence that the platform improves drug-development success, efficacy, safety, cost, or timelines. The IPO therefore marks a consequential commercial and clinical milestone, not proof that its approach works.
The IPO is a significant funding event for an AI-native biotech because it links the company’s AI strategy to a public-market financing and a defined clinical . Iambic says its platform may address challenges such as brain metastases, drug resistance, and dose-limiting toxicity, but these are stated design goals rather than independently demonstrated clinical outcomes.
MedCity News reports that Iambic has strategic partnerships with AbbVie, Bayer, Jazz Pharmaceuticals, Lundbeck, Revolution Medicines, and Takeda Pharmaceutical, and that Nvidia helped develop the technology and invested in the company. Those relationships indicate industry interest, but the source does not explain the partnerships’ specific deliverables or establish that they validate the platform’s medical performance.
The source is a reported secondary account. Its descriptions of the IPO, company plans, filing information, platform capabilities, and clinical status are attributed here to MedCity News; no independent confirmation or independent trial analysis is provided.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Which component of an AI application is the machine-learning model itself?
What to watch next
Watch for results from IAM1364’s Phase 1/1b trial, any start of a registrational trial, and clinical progress for IAM217 and IAM-C1. The source does not establish regulatory approval, commercial availability, treatment effectiveness, or access to Iambic’s platform for outside users.
The key near-term evidence will be safety, tolerability, pharmacokinetic, and efficacy data from IAM1364’s Phase 1/1b study. The source does not provide patient results, enrollment totals, trial dates, control-group information, or comparisons with existing HER2 therapies.
MedCity News reports that Iambic expects to begin a registrational trial as early as next year, but that timing is a company expectation and is not independently confirmed in the source. Whether regulators accept a pathway toward accelerated approval remains unknown.
Further updates should clarify whether IAM217 and IAM-C1 enter human testing, how the IPO funds are allocated in practice, and whether collaboration revenue continues to grow. The source does not document public access to Iambic’s platform, licensing terms, or pricing.